Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06202014 | Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC | unknown | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT05435313 | Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | unknown | Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 17, 2024 |
| clinicaltrials |
| NCT05962450 | Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy | unknown | Phase 2 | 84 | Beijing YouAn HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04617457 | Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas(HOLIPANC) | unknown | Phase 2 | 150 | University of CologneOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06198465 | Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma | unknown | Phase 2 | 24 | Xijing HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06192784 | Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-012) | unknown | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06197438 | Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer | unknown | Phase 2 | 36 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2024 | clinicaltrials |
| NCT02037048 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | unknown | Phase 2 | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 46 | Chinese PLA General HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05626569 | Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT05859477 | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer(NIVOFGFR2) | unknown | Phase 2 | 23 | Kidney Cancer Research BureauOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06171854 | caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.(ABACO) | unknown | Phase 2 | 33 | University of Campania Luigi VanvitelliOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06186609 | PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC | unknown | Phase 2 | 68 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04329429 | A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer | unknown | Phase 2 | 57 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05839197 | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC(CCGLC-010) | unknown | Phase 2 | 38 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy(DICI_PC) | unknown | Phase 1 / Phase 2 | 10 | Soonchunhyang University HospitalOTHER | 0 | Dec 15, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT05432934 | Transversus Abdominis Plane Blocks With and Without Dexamethasone(TAP-DEX) | unknown | Phase 1 / Phase 2 | 60 | University of SaskatchewanOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05578287 | RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer(DETECT) | unknown | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06153368 | Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05820906 | Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03729687 | Short Course Radiation Therapy Followed by Pre-operative Chemotherapy and Surgery in High-risk Rectal Cancer(LARCT-US) | unknown | Phase 2 | 280 | Uppsala UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05262335 | Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)(ALTER-G-001) | unknown | Phase 2 | 116 | Ruijin HospitalOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05580445 | Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 114 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05709171 | Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms | unknown | Phase 2 | 200 | Rigshospitalet, DenmarkOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05512520 | Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma(EC-CRT-003)(EC-CRT-003) | unknown | Phase 2 | 126 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06134193 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 41 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06134765 | Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer | unknown | Phase 2 | 89 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04999332 | Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer(LOTS) | unknown | Phase 2 | 58 | National Cheng-Kung University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT05376423 | To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence | unknown | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT05839470 | Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer | unknown | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 36 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 0 | Nov 15, 2023 | clinicaltrials |
| NCT04034459 | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC(AIO-KRK-0116) | unknown | Phase 2 | 109 | Ludwig-Maximilians - University of MunichOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04308837 | A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation | unknown | Phase 2 | 29 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04310176 | Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer(REVOLUTION) | unknown | Phase 2 | 200 | National Cancer Institute, NaplesOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06123455 | Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 60 | Tang-Du HospitalOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT00294827 | Liver Transplantation and Metastatic Colo-rectal Cancer. | unknown | Phase 2 | 25 | Oslo University HospitalOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06118047 | Crisaborole Ointment for Skin Toxicity Induced by Cetuximab(COSTIC) | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06120127 | Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence(IMPROVE) | unknown | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05781958 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | unknown | Phase 2 | 64 | Shen FengOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06111326 | BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 83 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT04753203 | Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients(ALCAP) | unknown | Phase 1 / Phase 2 | 65 | Korean Cancer Study GroupOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05785325 | RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05229874 | Effect of CNSI vs. ICG in Lymph Node Tracing During Gastrectomy(FUTURE-01) | unknown | Phase 2 | 96 | Hebei Medical UniversityOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT06089330 | A Study of JMT101 in Patients With Metastatic Colorectal Cancer | unknown | Phase 2 | 102 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Oct 18, 2023 | clinicaltrials |
| NCT03638297 | PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer(PCOX) | unknown | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05363007 | Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma(SINAI) | unknown | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05250843 | TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC | unknown | Phase 2 / Phase 3 | 90 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06078657 | IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) | unknown | Phase 2 | 46 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Oct 12, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 19, 2024source: clinicaltrials